Quest Diagnostics vs Fortrea
DGX and FTRE side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DGX and FTRE compare
Quest Diagnostics is the larger company, worth 14 times as much as Fortrea ($27.8B against $2.0B).
Quest Diagnostics grew revenue faster over the last twelve months (9.9% versus −3.4% for Fortrea).
Quest Diagnostics keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −2.6% at Fortrea.
Quest Diagnostics pays a dividend yielding 1.3%; Fortrea does not pay one.
Quest Diagnostics scores higher on the StockData Score (12 against 4 for Fortrea), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DGX | FTRE |
|---|---|---|
| Size and price | ||
| Market cap | $27.8B | $2.0B |
| Share price | $251.82 | $21.29 |
| Change, 1 year | 44.1% | 104% |
| Change, 5 years | 79.2% | – |
| Beta (5Y) | 0.33 | 1.49 |
| Employees | 57K | 14K |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 3 (better) | 0 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 26.8× | – |
| P/S | 2.4× | 0.8× (better) |
| P/B | 3.7× (better) | 3.8× |
| EV/EBITDA | 15.0× (better) | 31.3× |
| P/FCF | 20.6× | 12.0× (better) |
| PEG | 8.47 | – |
| FCF yield | 4.9% | 8.3% (better) |
| Fair value | $251.80 | $17.16 |
| Margin of safety | −0.01% (better) | −24.1% |
| Growth | ||
| Revenue growth (TTM) | 9.9% (better) | −3.4% |
| Revenue growth, 5Y average | 3.2% | – |
| Net income growth (TTM) | 11.8% | – |
| EPS growth (TTM) | 13.2% | – |
| EPS growth, 5Y average | −3.5% | – |
| Profitability | ||
| Gross margin | 33.1% (better) | 20.0% |
| Operating margin | 14.1% (better) | 0.48% |
| Net margin | 9.2% (better) | −2.6% |
| FCF margin | 11.7% (better) | 6.3% |
| Return on equity | 14.4% (better) | −12.3% |
| Return on invested capital | 10.0% (better) | 0.69% |
| Financial health | ||
| Debt / equity | 0.75 (better) | 1.98 |
| Net debt / EBITDA | 2.27 (better) | 9.12 |
| Current ratio | 1.59 (better) | 0.97 |
| Altman Z-score | 3.76 (better) | 0.80 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.3% | – |
| Payout ratio | 34.2% | – |
| Shareholder yield | 1.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.1% | 105% |
| Held by insiders | 0.47% | 4.0% |
| Insider net buying, 12 months | −$37.0M | −$4.7M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.1% | 13.8% |
Go deeper
- DGX stock overview
- DGX income statement
- DGX valuation and score
- FTRE stock overview
- FTRE income statement
- FTRE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.